Differences in risk factors for hepatitis B, hepatitis C, and human immunodeficiency virus infection by ethnicity: A large population-based cohort study in British Columbia, Canada

被引:5
作者
Binka, Mawuena [1 ]
Butt, Zahid Ahmad [2 ]
McKee, Geoffrey [1 ]
Darvishian, Maryam [3 ]
Cook, Darrel [1 ]
Wong, Stanley [1 ]
Yu, Amanda [1 ]
Alvarez, Maria [1 ]
Samji, Hasina [1 ,4 ]
Wong, Jason [1 ,5 ]
Krajden, Mel [1 ,6 ]
Janjua, Naveed Zafar [1 ,5 ]
机构
[1] British Columbia Ctr Dis Control, 655 West 12th Ave, Vancouver, BC V5Z 4R4, Canada
[2] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON, Canada
[3] British Columbia Canc Res Ctr, Vancouver, BC, Canada
[4] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada
[5] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada
[6] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada
关键词
Coinfection; Ethnicity; Hepatitis B virus; Hepatitis C virus; Substance use; HEALTH-CARE; VIRAL-HEPATITIS; MIGRANT CHINESE; HIV; PREVALENCE; HCV; COINFECTION; IMMIGRANT; BARRIERS; PEOPLE;
D O I
10.1016/j.ijid.2021.03.061
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: Addressing the needs of ethnic minorities will be key to finding undiagnosed individuals living with hepatitis B (HBV), hepatitis C (HCV), or human immunodeficiency virus (HIV). To inform screening initiatives in British Columbia (BC), Canada, the factors associated with HBV and/or HCV and/or HIV infection among different ethnic groups within a large population-based cohort were assessed. Methods: Persons diagnosed with HBV, HCV, or HIV in BC between 1990 and 2015 were grouped as East Asian, South Asian, Other Visible Minority (African, Central Asian, Latin American, Pacific Islander, West Asian, unknown ethnicity), and Not a Visible Minority, using a validated name-recognition software. Factors associated with infection within each ethnic group were assessed with multivariable multinomial logistic regression models. Results: Participants included 202 521 East Asians, 126 070 South Asians, 65 210 Other Visible Minorities, and 1 291 561 people who were Not a Visible Minority, 14.4%, 3.3%, 4.5%, and 6.3% of whom had HBV and/ or HCV and/or HIV infections, respectively. Injection drug use was most prevalent among infection positive people who were Not a Visible Minority (22.1%), and was strongly associated with HCV monoinfection, HBV/HCV coinfection, and HCV/HIV coinfection, but not with HBV monoinfection among visible ethnic minorities. Extreme material deprivation and social deprivation were more prevalent than injection drug use or problematic alcohol use among visible ethnic minorities. Conclusions: Risk factor distributions varied among persons diagnosed with HBV and/or HCV and/or HIV of differing ethnic backgrounds, with lower substance use prevalence among visible minority populations. This highlights the need for tailored approaches to infection screening among different ethnic groups. (c) 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).
引用
收藏
页码:246 / 253
页数:8
相关论文
共 49 条
  • [1] Bechini A, 2016, J Prev Med Hyg, V57, pE51
  • [2] Differing profiles of people diagnosed with acute and chronic hepatitis B virus infection in British Columbia, Canada
    Binka, Mawuena
    Butt, Zahid A.
    Wong, Stanley
    Chong, Mei
    Buxton, Jane A.
    Chapinal, Nuria
    Yu, Amanda
    Alvarez, Maria
    Darvishian, Maryam
    Wong, Jason
    McGowan, Gina
    Torban, Mikhail
    Gilbert, Mark
    Tyndall, Mark
    Krajden, Mel
    Janjua, Naveed Z.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (11) : 1216 - 1227
  • [3] Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016
    Bundle, Nick
    Balasegaram, Boorla
    Parry, Sarah
    Ullah, Sadna
    Harris, Ross J.
    Ahmad, Karim
    Foster, Graham R.
    Tour, Cheuk Y. W.
    Orkin, Chloe
    [J]. EUROSURVEILLANCE, 2019, 24 (27) : 17 - 25
  • [4] Effect of opioid-substitution therapy and mental health counseling on HIV risk among hepatitis C-infected individuals
    Butt, Zahid A.
    Shrestha, Nabin
    Gesink, Dionne
    Murti, Michelle
    Buxton, Jane A.
    Gilbert, Mark
    Balshaw, Robert F.
    Wong, Stanley
    Kuo, Margot
    Wong, Jason
    Yu, Amanda
    Alvarez, Maria
    Samji, Hasina
    Roth, David
    Consolacion, Theodora
    Hull, Mark W.
    Ogilvie, Gina
    Tyndall, Mark W.
    Krajden, Mel
    Janjua, Naveed Z.
    [J]. CLINICAL EPIDEMIOLOGY, 2018, 10 : 1127 - 1145
  • [5] A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia
    Butt, Zahid Ahmad
    Shrestha, Nabin
    Wong, Stanley
    Kuo, Margot
    Gesink, Dionne
    Gilbert, Mark
    Wong, Jason
    Yu, Amanda
    Alvarez, Maria
    Samji, Hasina
    Buxton, Jane A.
    Johnston, James C.
    Cook, Victoria J.
    Rothe, David
    Consolacion, Theodora
    Murti, Michelle
    Hottes, Travis S.
    Ogilvie, Gina
    Balshaw, Robert
    Tyndall, Mark W.
    Krajden, Mel
    Janjua, Naveed Z.
    [J]. PLOS ONE, 2017, 12 (08):
  • [6] HCV co-infection in HIV positive population in British Columbia, Canada
    Buxton, Jane A.
    Yu, Amanda
    Kim, Paul H.
    Spinelli, John J.
    Kuo, Margot
    Alvarez, Maria
    Gilbert, Mark
    Krajden, Mel
    [J]. BMC PUBLIC HEALTH, 2010, 10
  • [7] Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of the Liver and Association of Medical Microbiology and Infectious Disease Canada
    Coffin, Carla S.
    Fung, Scott K.
    Alvarez, Fernando
    Cooper, Curtis L.
    Doucette, Karen E.
    Fournier, Claire
    Kelly, Erin
    Ko, Hin Hin
    Ma, Mang M.
    Martin, Steven R.
    Osiowy, Carla
    Ramji, Alnoor
    Tam, Edward
    Villeneuve, Jean Pierre
    [J]. CANADIAN LIVER JOURNAL, 2018, 1 (04): : 156 - 217
  • [8] Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013
    Degenhardt, Louisa
    Charlson, Fiona
    Stanaway, Jeff
    Lamey, Sarah
    Alexander, Lily T.
    Hickman, Matthew
    Cowie, Benjamin
    Hall, Wayne D.
    Strang, John
    Whiteford, Harvey
    Vos, Theo
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (12) : 1385 - 1398
  • [9] Knowledge, Attitudes, and Behaviors Related to Hepatitis C Screening and Treatment among Health Care Providers in Washington, DC
    Doshi, Rupali Kotwal
    Ruben, Max
    Drezner, Kate
    Lachmann, Alexandra
    Kuo, Irene
    Chanes-Mora, Paola
    Varga, Leah
    Saafir-Callaway, Brittani
    Visconti, Adam
    Kharfen, Michael
    [J]. JOURNAL OF COMMUNITY HEALTH, 2020, 45 (04) : 785 - 794
  • [10] Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs
    Doyle, Michael
    Maher, Lisa
    Graham, Simon
    Wand, Handan
    Iversen, Jenny
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PUBLIC HEALTH, 2018, 42 (01) : 52 - 56